edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Ultimovacs
Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Ultimovacs — 7 videos in collection
Ultimovacs is a Scandinavian-based biotech focused on developing novel immunotherapies in combination with checkpoint inhibitors against cancer. Its lead product candidate, UV1, is a universal off-the-shelf peptide-based vaccine being studied in ongoing Phase II clinical trials across five indications. The innovative oncology vaccine targets the cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of settings and would increase accessibility.
In this interview, Ultimovacs CMO Jens Bjørheim recaps the company’s progress and provides a preview of the upcoming rich newsflow.
Get access to the very latest content matched to your personal investment style.